MetaVia Achieves 9.1% Weight Loss and Launches 48mg/64mg Titration Study
MetaVia’s DA-1726 Phase 1 trial achieved 9.1% mean weight loss in the 48 mg cohort and initiated dosing of the first patient in the 16-week Part 3 study testing 48 mg one-step and 64 mg two-step regimens, with data due in Q4 2026. Q1 R&D expenses fell to $2.1 million.
1. Phase 1 Part 3 Dosing Milestone
MetaVia initiated dosing of the first patient in its Phase 1 Part 3 study of DA-1726, evaluating a one-step 48 mg titration and a two-step 64 mg regimen over 16 weeks following IRB approval. This approach aims to safely reach higher therapeutic doses with improved tolerability compared to existing therapies.
2. Early Phase 1 Results Demonstrate Weight Loss and Metabolic Benefits
In the non-titrated 48 mg cohort, DA-1726 achieved an average 9.1% weight loss over eight weeks, along with statistically significant waist circumference reductions, glucose control improvements, and direct liver benefit, all with a favorable safety profile. These findings support DA-1726’s dual GLP-1/glucagon mechanism as potentially best-in-class.
3. Q1 2026 Financial Performance
Research and development expenses decreased to $2.1 million for Q1 2026 from $2.3 million year-over-year, driven by lower direct product development costs. General and administrative expenses rose to $1.9 million, reflecting higher consulting, franchise tax and legal expenditures, while a $9.3 million financing completed in January bolstered the company’s cash runway.
4. Upcoming Data Readouts and Intellectual Property
MetaVia expects to report Part 3 data in the fourth quarter of 2026 and plans to present additional 48 mg cohort liver data at a major hepatology congress. The company also holds 48 granted and pending patents for vanoglipel and 39 for DA-1726, providing protection into 2035 and 2041, respectively.